Locally Recurrent Rectal Cancer QoL Is Valid Patient-Reported Outcome Measure
FRIDAY, June 9, 2023 (HealthDay News) -- A new locally recurrent rectal cancer (LRRC) quality of life (QoL) measure is a valid patient-reported outcome measure (PROM), according to a study published in the May issue of eClinicalMedicine.
Deena P. Harji, M.B.B.S., Ph.D., from the University of Leeds in the United Kingdom, and colleagues developed a disease-specific, psychometrically robust, and validated PROM for use in LRRC. A total of 117 adults in the United Kingdom and Australia with an existing or previously treated LRRC within the last two years completed the proposed LRRC-QoL, European Organisation for Research and Treatment of Cancer Quality of Life-C29 (EORTC QLQ-CR29), and Functional Assessment of Cancer Therapy-Colorectal (FACT-C) questionnaires. Nine multi-item scales (health care services, psychological impact, pain, urostomy-related symptoms, lower limb symptoms, stoma, sexual function, sexual interest, and urinary symptoms) and three single items were included in the LRRC-QoL measure.
The researchers found that overall reliability was supported by Cronbach's Alpha and Intraclass correlation values of >0.7 across the majority of scales. Validity was convergent between the LRRC-QoL pain scale and FACT-C Physical Well Being scale; LRRC-QoL psychological impact scale and EORTC QLQ-CR29 Body Image scale and the FACT-C Emotional Well-Being scale; and LRRC-QoL urinary symptoms scale and EORTC QLQ-CR29 Urinary Frequency scale. For gender, disease location, treatment intent, and recurrent disease, known-groups validity was demonstrated.
"The LRRC-QoL has the potential to transform outcome assessment in locally recurrent rectal cancer. In clinical practice, the LRRC-QoL will be able to quantify patient symptoms, experience, and overall satisfaction," a coauthor said in a statement. "This will lead to the disclosure and identification of potential issues not routinely reported and will aid the early detection and subsequent monitoring of symptoms."
Related Posts
El senador John Fetterman mejora, aunque todavía no se sabe cuándo volverá al trabajo
VIERNES, 24 de marzo de 2023 (HealthDay News) -- Es probable que el senador John...
Nirogacestat Beneficial for Progressing Desmoid Tumors
THURSDAY, March 9, 2023 (HealthDay News) -- For adults with progressing desmoid...
Fully Online College Classes Tied to Greater Psychological Distress
FRIDAY, Dec. 9, 2022 (HealthDay News) -- Fully remote college classes were...
Se necesita un grupo más diverso de donantes de sangre para ayudar a los pacientes con anemia drepanocítica
MARTES, 6 de septiembre de 2022 (HealthDay News) -- Una red que recibe y...